Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.
10.1007/s13238-017-0400-z
- Author:
Zhenguang WANG
1
;
Yelei GUO
1
;
Weidong HAN
2
Author Information
1. Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China.
2. Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, 100853, China. hanwdrsw69@yahoo.com.
- Publication Type:Journal Article
- Keywords:
CAR-T;
adoptive cell therapy;
cancer treatment;
chimeric antigen receptor;
engineered T cells
- MeSH:
Animals;
Humans;
Immunity, Cellular;
Immunotherapy;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;
immunology;
pathology;
therapy;
Receptors, Antigen, T-Cell;
immunology;
Recombinant Fusion Proteins;
immunology;
T-Lymphocytes;
immunology;
transplantation
- From:
Protein & Cell
2017;8(12):896-925
- CountryChina
- Language:English
-
Abstract:
Chimeric antigen receptor (CAR) is a recombinant immunoreceptor combining an antibody-derived targeting fragment with signaling domains capable of activating cells, which endows T cells with the ability to recognize tumor-associated surface antigens independent of the expression of major histocompatibility complex (MHC) molecules. Recent early-phase clinical trials of CAR-modified T (CAR-T) cells for relapsed or refractory B cell malignancies have demonstrated promising results (that is, anti-CD19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL)). Given this success, broadening the clinical experience of CAR-T cell therapy beyond hematological malignancies has been actively investigated. Here we discuss the basic design of CAR and review the clinical results from the studies of CAR-T cells in B cell leukemia and lymphoma, and several solid tumors. We additionally discuss the major challenges in the further development and strategies for increasing anti-tumor activity and safety, as well as for successful commercial translation.
